Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 15/20 | 0.55 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.55 |
| ▸ | BRD7 | Q9NPI1 | 6/20 | 0.55 |
| ▸ | BRD2 | P25440 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TAF1 | P21675 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.40 |
| ▸ | BRD8 | Q9H0E9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22317951 | 0.85 | BRD9 (0.59) | BRD4BRD9BRD7BRD2CYP2D6 | |
| SCHEMBL1719807 | 0.75 | BRD4 (0.59) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL19869876 | 0.71 | BRD4 (1.00) | BRD4BRD9BRD7BRD2CYP2D6 | |
| SCHEMBL19857642 | 0.70 | BRD4 (0.74) | BRD4BRD9BRD7BRD2CYP2D6 | |
| SCHEMBL19869887 | 0.70 | BRD4 (0.64) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL26141999 | 0.68 | BRD4 (0.81) | BRD4BRD9BRD7BRD2CYP2D6 | |
| Hydrochloric Acid SCHEMBL5317549 | 0.66 | BRD9 (0.60) | BRD4BRD9BRD7BRD2CYP2D6 | |
| SCHEMBL19930813 | 0.64 | SMN1; SMN2 (0.59) | BRD4BRD9BRD7 | |
| SCHEMBL19869875 | 0.64 | BRD4 (1.00) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL19931260 | 0.64 | BRD4 (0.49) | BRD4BRD9BRD7BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD7 149/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD4 42/4885BRD9 290/4885BRD7 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.